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Antimicrobial resistance (AMR) has increased world­
wide to the extent that it is now regarded as a global 
public health crisis. As acquired resistance is driven 
mainly by the exposure of bacteria to commonly 
prescribed antimicrobial agents, pragmatic responses to 
this problem should be the promotion of judicious use of antimicrobials 
and prevention of infections that would require antimicrobial treatment. 
The efficacy of both bacterial and viral vaccines in the reduction of 
antimicrobial prescriptions has been well described and as such they are 
a key strategy in the fight against AMR and a crucial component of a 
comprehensive antimicrobial stewardship (AMS) programme.
Bacterial vaccines
By targeting bacterial pathogens:
• Vaccines directly reduce the need for antibiotics by providing 
direct protection from bacterial disease, regardless of whether the 
organism is resistant to specific antimicrobials or not. 
• Vaccines may inhibit carriage by decreasing acquisition and 
colonisation by bacteria, specifically those targeted by the vaccine.
• Vaccines further reduce overall antibiotic consumption owing to 
indirect protection. This relates to the prevention of or reduction 
in transmission of pathogenic bacteria between unvaccinated 
members of the community.
Considering these factors, one of the best documented examples of 
the crucial role of vaccination as an adjunct to an AMS programme 
has been the pneumococcal conjugate vaccines (PCVs) – the main 
focus of this article.
Pneumococcal conjugate vaccines 
Accumulated evidence suggests that the 13­valent PCV (PCV13) has 
reduced much of the residual burden of pneumococcal diseases still 
present in children after the  introduction of PCV7.[1] This includes 
colonisation, and invasive, mucosal and drug­resistant pneumococcal 
diseases, and relates to the impact of PCV13 on the ‘pneumococcal 
mucosal trio’ of nasopharyngeal carriage, subsequent acute otitis 
media (AOM) and pneumonia. 
The reduction in carriage of serotypes with a high capacity to 
colonise may also contribute to a reduction in antibiotic resistance, 
spread and burden of pneumococcal diseases. Reductions in vaccine 
serotype and all­type invasive pneumococcal disease have also been 
reported in age groups not eligible for vaccination, demonstrating 
the extraordinary impact of indirect protection. Of note, this pheno­
menon extends to mortality, where a substantial population­level 
decline in pneumococcal­related mortality of nearly 30% was recently 
found among the unvaccinated population.[2] 
Impact of pneumococcal conjugate vaccines on 
pneumococcal disease 
In South Africa (SA), Von Gottberg et al.[3] recently demonstrated an 
89% reduction in the incidence of invasive pneumococcal disease by 
PCV7 serotypes within 4 years of their introduction among vaccinated 
children <2 years of age (direct effect), and a 57% reduction among 
unvaccinated adults 25 ­ 44 years of age (indirect effect). In a recent 
matched, case­control study Cohen et al.[4] similarly documented the 
efficacy of PCV7 using a two plus one schedule (6 and 14 weeks, and 
9 months) among HIV­uninfected and ­exposed SA children. 
Within the first 2 years of a PCV13 immunisation programme 
in Nicaragua, lower rates of hospitalisation and outpatient visits for 
pneumonia among children of all ages were observed.[5]  In Israel, in a 
prospective, long­term, active surveillance survey, a rapid and sharp 
2­step decline in pneumococcal and all­cause AOM incidence (with 
near­elimination of PCV13 disease) in children aged <2 years was noted 
following sequential PCV7/PCV13 introduction.[6] In the USA, after the 
introduction of PCV13, isolation of Streptococcus pneumoniae declined in 
children with chronic sinusitis, including a substantial reduction of PCV13 
serotypes, predominantly serotype 19A.[7]
The protective effect of the pneumococcal Haemophilus influenzae 
protein D conjugate vaccine (PHiD­CV10) for the prevention of 
AOM caused by S. pneumoniae and non­typeable H. influenzae has 
been documented at 52.6% (for pneumococcal vaccine serotypes) 
and 35.3%, respectively.[8] Vaccine efficacy against any episode of ear, 
nose and throat­referred AOM during per­protocol follow­up was 
34% (95% confidence interval 21 ­ 45).
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Vaccination may prevent bacterial infections and decrease the potential for transmission. Some effective vaccines may reduce bacterial 
colonisation and exposure to antimicrobials by minimising the spread of resistant strains; in this regard, a substantial indirect immunity has 
been demonstrated that protects unvaccinated members of society. One of the best documented examples of the crucial role of vaccination 
has been an adjunct to an antimicrobial stewardship programme. Pneumococcal conjugate vaccines (PCVs), for example, target the most 
virulent pneumococcal serotypes, which are linked to invasive disease and associated with antibiotic resistance. In this regard, recent local 
data highlight the remarkable impact of the sequential introduction of 7­ and 13­valent PCV (PCV7/PCV13) on the incidence of penicillin­, 
ceftriaxone­ and multidrug­resistant pneumococcal infections in South Africa in only 4 years. Equally impressive have been vaccines 
directed towards viruses such as influenza, which also have direct and indirect effects on antibiotic consumption. 
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Impact of pneumococcal conjugate 
vaccines on antibiotic resistance 
As depicted in Fig. 1, the introduction of 
PCV7 in SA in 2009, followed by PCV13 in 
2011, led not only to a dramatic reduction 
in penicillin­ (82%) and ceftriaxone­resistant 
(85%) pneumococcal infections, but also to 
multidrug­resistant (MDR) disease (84%).[3] 
These remarkable results are supported by the 
matched case­control study by Cohen et al.,[4] 
confirming that PCV may have a substantial 
impact on reducing the prevalence of 
MDR pneumococcal disease, as has been 
demonstrated in other settings.
Impact of pneumococcal conjugate 
vaccines on antibiotic use 
Several studies were conducted to evaluate 
the direct impact of PCV in reducing 
antibiotic prescriptions and respiratory 
illnesses in children. A 5.4% reduction in 
antibiotic prescriptions was recorded after 
the introduction of PCV7 at the Kaiser 
Permanente clinics in Northern California, 
as well as a 12.6% decrease in second­line 
antibiotic prescriptions.[9] Overall, PCV7 
prevented 35 antibiotic prescriptions per 
100 vaccinated children. Furthermore, risk 
reductions of 15%, 16% and 17% for upper 
respiratory tract infections, lower respiratory 
tract infections, and AOM, respectively, as 
well as a 17% reduction in antibiotic use, were 
observed in children who were given PCV9.[10] 
In a study of privately insured children 
in the USA, a 41.9% reduction in antibiotic 
prescriptions for AOM was demonstrated 
from 1997 to 2004 following implementation 
of the PCV7 immunisation programme.[11]  It 
has been predicted that universal vaccination 
of children with PCV13 would reduce AOM 
by an additional 16.3 million cases in the 
USA compared with vaccination with PCV7. 
The PHiD­CV10 vaccine is also effective; 
using the impact of this vaccine on outpatient 
antibiotic prescriptions, specifically those 
recommended by the Finnish national treatment 
guidelines for AOM as the primary endpoint 
assessment, an 8% efficacy was found.[12]
Need for a concurrent 
programme promoting 
appropriate antibiotic 
use with widespread 
vaccination 
Increasing evidence suggests that a campaign 
to increase vaccine uptake should include a 
programme to promote appropriate antibiotic 
use as this appears to have synergistic effects, 
which seem to be of particular relevance to 
PCV.
• A reduction in antibiotic consumption in 
primary care in conjunction with an increase 
in PCV uptake had a synergistic effect on 
carriage of resistant pneumococci in the 
cohort studied.[13] Risks for penicillin non­
susceptible S. pneumoniae carriage were 4.2% 
for immunised children who had not received 
antibiotics in the preceding 3 months, 8.6% 
for immunised patients who had received 
antibiotics, 10.3% for non­immunised 
patients who had not received antibiotics, 
and 16.2% for non­immunised children who 
had received antibiotics (p<0.001).
• Hicks et al.[14] recently demonstrated that 
after the introduction of PCV7 vacci­
nation, if antibiotic prescribing remained 
high (particularly cephalosporins and long­
acting macrolides/azalides), the proportion 
of non­susceptible invasive pneumococcal 
disease due to non­vaccine serotypes 
also remained high, suggesting that 
local prescribing practices continue to 
contribute to local resistance patterns. 
Studies such as these reinforce the need for 
concomitant, judicious antibiotic utilisation 
intervention programmes.
Viral vaccines
In addition to antibacterial vaccines, such 
as those against diphtheria, pertussis and 
H. influenzae type b, vaccines for viruses 
can also have direct and indirect effects on 
antibiotic consumption by reducing:
• Viral infections and fever syndromes, 
where antibiotics are frequently and 
inappropriately used. 
• Complications of viral infections (e.g. 
secondary bacterial infection) requiring 
antibiotics.
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Fig. 1. Rates of disease caused by non-susceptible pneumococcal isolates among all ages (A), and among 
children <2 years of age (B), by antimicrobial agent and year, SA, 2005 - 2012 (adapted and reproduced with 
permission from Von Gottberg et al.[3] (PCV7 and PCV13 were introduced in 2009 and 2011, respectively)).
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In Finland, 42% of children suffering from seasonal influenza 
receive antibiotics inappropriately, but in a study in Ontario, 
Canada, the increased use of influenza vaccination following 
recommendations for universal use resulted in a 64% decrease in 
antimicrobial prescriptions for influenza­associated respiratory 
disease.[15]
Targeting selected patient groups, such as postpartum mothers, 
is also beneficial. Influenza vaccination reduced acute respiratory 
illnesses, febrile episodes, influenza­like illnesses and healthcare 
visits in neonates born to vaccinated mothers by 37.7%, 50.3%, 53.5% 
and 41.8%, respectively, and also reduced antibiotic prescriptions 
by 45.4%.[16] Madhi et al.[17] recently documented the impact of 
influenza vaccination on pregnant women in SA. The data showed 
that vaccination provided protection in pregnant HIV­uninfected 
and ­infected women and that vaccination was also effective in HIV­
unexposed infants up to 24 weeks after birth. 
Conclusion
By reducing the prevalence of infection through vaccination (bacterial 
or viral) the number of patients visiting medical facilities are 
minimised, which in the majority of cases avoids the indiscriminate 
use of antibiotics. Vaccination, therefore, could limit the development 
of AMR by decreasing the likelihood that bacteria targeted by certain 
vaccines would be exposed to antimicrobial agents. In this regard, the 
results of the Community Acquired Pneumonia Immunization Trial 
in Adults (CAPITA), an efficacy study of PCV13 in the prevention 
of a first episode of vaccine serotype­specific pneumococcal CAP 
in 85  000 adults aged ≥65 years, are eagerly awaited. Innovative 
vaccines targeting hospital­acquired infections are currently under 
investigation and are also an exciting prospect for the future. 
Therefore, public authorities are increasingly acknowledging the 
role of vaccination in the fight against AMR and consider it a key 
intervention in national AMS programmes. 
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